Active Ingredient History

NOW
  • Now
Brinzolamide reduces the amount of fluid in the eye, which decreases pressure inside the eye. Brinzolamide is a carbonic anhydrase inhibitor that is FDA approved for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Common adverse reactions include abnormal taste in mouth and blurred vision. The concomitant administration of brinzolamide and oral carbonic anhydrase inhibitors is not recommended. Plus, in patients treated with oral carbonic anhydrase inhibitors, rare instances of acid-base alterations have occurred with high-dose salicylate therapy.   NCATS

  • SMILES: CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
  • InChIKey: HCRKCZRJWPKOAR-JTQLQIEISA-N
  • Mol. Mass: 383.507
  • ALogP: 0.09
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$11.0248 - $14.7307

United States

$22.3810 - $32.9190
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( brimonidine (alphagan), brinzolamide (azopt) - other name: simbrinza 0.2%/1% ophthalmic suspension )
al-4862 | alcon brand of brinzolamide | allphar brand of brinzolamide | azopt | brinzolamide | brinzolamide / brimonidine tartrate | brinzolamide / timolol maleate

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue